Novel Bispecific CAR-T Cells Against Hematological Cancers
Dr. Vita Golubovskaya, Director of R&D at ProMab will be hosting a webinar with Agilent that incorporates some [...]
Dr. Vita Golubovskaya, Director of R&D at ProMab will be hosting a webinar with Agilent that incorporates some [...]
Interested in learning more about Bispecific Antibody Engineering? ProMab will be hosting a webinar encompassing our Bispecific Antibody [...]
ProMab Biotechnologies is the world’s first CRO committed to improving human health with a focus on immunotherapy, specifically [...]
ProMab’s humanized CD19 CAR-T platform is a CAR T-cell therapy approved for adults with treatment of relapsed and [...]
BERKELEY, Calif. & RICHMOND, Calif.–(BUSINESS WIRE)–Caribou Biosciences, Inc., a leading CRISPR genome editing company, and ProMab Biotechnologies [...]
The 2019 novel coronavirus (2019-nCoV) is a new virus that causes respiratory illness in people and can spread [...]
ProMab has recently had our work published in JoVE on the real-time cytotoxicity assay (RTCA) that we use [...]
Initially Launching a Novel, High-Affinity BCMA CAR Targeting NK Cell Development Candidate For Multiple Myeloma, With An Option [...]
CAR-TCR Summit 2019 Come visit the ProMab team and learn about our new products & services Booth #50 [...]
ASCO Annual Meeting 2019 Come visit the ProMab team and learn about our new products & services Booth [...]
AACR Annual Meeting 2024. Come visit the ProMab team and learn about our new products & services at our booth and poster session. [...]
Vita Goblubovskaya, PhD, discusses advancements in mRNA-LNP technology, including bispecific antibodies and CAR technology [...]